In this Satellite Symposium, titled “All you need to know when managing chronic lymphocytic leukemia (CLL) or indolent lymphoma patients under Bruton’s tyrosine kinase (BTKi) treatment,” a panel of hematology experts discussed topics such as an introduction to BTKis for CLL in clinical practice, resistance mutations and BTKi switching, the safety profile of BTKis and management of cardiovascular events, and pharmacokinetics and pharmacodynamics of BTKis.

The slides are available for download here.